drugset / Trial / NCT07708753
A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of SYS6043 versus investigator's choice chemotherapy in participants with platinum-resistant ovarian cancer, primary peritoneal, or fallopian tube cancer.
Timeline
- Start
- 2026-07-15
- Primary completion
- 2029-10-01
- Completion
- 2030-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | SYS6043 | Other / unclassified | — | — |
| Comparator | Topotecan | Small molecule | 4 mg/m2 | — |